Vienna, Austria

ESTRO 2023

Session Item

Sunday
May 14
16:45 - 17:45
Strauss 3
Head and neck & physics
Adam Chicheł, Poland;
Silke Tribius, Germany
2560
Proffered Papers
Brachytherapy
17:05 - 17:15
ESTRO abstract: The global Ruthenium Eye applicator survey - physicist responses
Frank-André Siebert, Germany
OC-0633

Abstract

ESTRO abstract: The global Ruthenium Eye applicator survey - physicist responses
Authors:

Lotte Stubkjaer Fog1,2, Marisol De Brabandere3, Elisa Placidi4, Andrea Slocker5, Luca Tagliaferri6, Ȧsa Carlsson Tedgren7, Michael Andrássy8, Carmen Schulz9, Evelyn Chibeka Chimfwembe10, Frank-Andre Siebert (chair of BRAPHYQS)11

1Alfred Health Radiation Oncology, Medical Physics, Melbourne, Australia; 2Royal Victorian Eye and Ear Hospital, Ocular Oncology, Melbourne, Australia; 3UZ Leuven, Medical Physics, Leuwen, Belgium; 4Policlinico Universitario Agostino Gemelli IRCCS, Medical Physics, Rome, Italy; 5 Catalan Institute of Oncology, Medical Physics, Barcelona, Spain; 6Policlinico Universitario Agostino Gemelli IRCCS, Radiation Oncology, Rome, Italy; 7Linköping University, Karolinska Institute and Karolinska University hospital, Medical Physics, Linköping, Sweden; 8Eckert and Ziegler, BEBIG, Berlin, Germany; 9Eckert and Ziegler , Bebig, Berlin, Germany; 10ESTRO, ., Bruxelles, Belgium; 11UKSH, Campus Kiel, Clinic of Radiotherapy, Kiel, Germany

Show Affiliations
Purpose or Objective

Ruthenium plaque brachytherapy is an eye-preserving treatment for choroidal melanoma with good treatment outcomes [1]. It is a niche treatment, performed in only about 100 clinics worldwide [2].

There are considerable variations in clinical practice. A practice survey can be used to map practice, and may help practice improvement in some clinics.

In 2021, BRAPHYQS (Physics working group of GEC-ESTRO) Working Package (WP) 22 decided to undertake  two such global practice surveys: one aimed at physicists and one at physicians.  This abstract describes the physicist survey results.

Material and Methods

A physicist survey with 17 questions was created using Surveymonkey TM (Momentive Inc). The response options were specified using dropdown lists whenever possible, however each question had an “other” or “comment” response option to allow the responder to add free text  information. The last few questions were open questions allowing text answers to map the responders thoughts on current, and future, clinical practice.  

Potential responders were contacted through the ESTRO newsletter, the MedPhys mailing list, national medical physics mailing lists and professional networks. The survey opened on March 1st 2022 and closed on July 31st 2022.

Results

76 responses were received, of which 11 were excluded. Of the remaining 65, 25 were anonymous. 28 were from Europe, 3 from the African continent, 5 from Australia and New Zealand, 2 from the US.

26 clinics do not do any  commissioning and acceptance testing, 26 clinics  do this with an in-house built phantom.  

35  clinics do not measure percentage depth doses (PDDs), 28 clinics measure PDDs with a range of detectors - however only 2 clinics use the measured PDDs for planning.  43 clinics do not measure any off-axis data.

49 clinics use the  value from the calibration certificate in planning calculations.

41 clinics use an in-house spreadsheet for treatment planning. Those that use image-based planning use a variety of images for this.

2 clinics use radiobiological corrections to their treatment planning.

In 9 of the clinics, no independent check on the calculation is carried out.

10 clinics would like to introduce image-based planning, and 22 would like to change otther aspects of their treatment process.

The responders reported following a variety of guidelines.

Conclusion

Ruthenium plaque brachytherapy practice is  starkly different from other radiation oncology practice in several ways. Pertinently, the majority of clinics do not measure PDDs or profiles on new plaques, and use spreadsheets for treatment planning. Surveyed staff expressed a range of desirable improvements to clinical practice. A transition to image-based planning is one of the most desirable changes named by responders, and this would likely improve tumour control.



References
[1] Acta Oncologica, 59:8, 918-925, DOI: 10.1080/0284186X.2020.1762925
[2] Private communication, Eckert & Ziegler BEBIG, Germany